<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PENTAZOCINE AND NALOXONE - pentazocine hydrochloride and naloxone hydrochloride tablet </strong><br>Keltman Pharmaceuticals Inc.<br></p></div>
<h1>Pentazocine and<br> Naloxone<br> Hydrochlorides<br> Tablets USP<br> Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED SECTION</h1>
<p class="First"><span class="Bold">Analgesic for Oral use Only</span></p>
<table frame="hsides">
<thead><tr class="First Last"><td class="Lrule" align="left" colspan="2" valign="top"></td></tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="left" valign="top">Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See <a href="#A37F1893-B7D1-4331-B73C-EA1493CE10A2">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a> section.)</td>
<td class="Rrule" align="left" valign="top"></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Pentazocine and naloxone hydrochlorides tablets USP contain pentazocine hydrochloride USP, equivalent to 50 mg base, a member of the benzazocine series (also known as the benzomorphan series), and naloxone hydrochloride USP, equivalent to 0.5 mg base.</p>
<p>Pentazocine and naloxone hydrochlorides tablets are an analgesic for oral administration.</p>
<p>Chemically, pentazocine hydrochloride is (2<span class="Italics">R</span>*, 6<span class="Italics">R</span>*, 11<span class="Italics">R</span>*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol hydrochloride, a white, crystalline substance soluble in acidic aqueous solutions. It has the following structural formula:</p>
<div class="Figure">
<img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05a17f16-c982-4a54-80cd-079959ab49a7&amp;name=pentazocine-figure-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">19</span>H<span class="Sub">27</span>NO•HCI        Molecular Weight 321.88</p>
</div>
<p>Chemically, naloxone hydrochloride is 17-AIlyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride. It is a slightly off-white powder, and is soluble in water and dilute acids. It has the following structural formula:</p>
<div class="Figure">
<img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05a17f16-c982-4a54-80cd-079959ab49a7&amp;name=pentazocine-figure-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">19</span>H<span class="Sub">21</span>N0<span class="Sub">4</span>•HCI        Molecular Weight 363.84</p>
</div>
<p>Each tablet, for oral administration, contains pentazocine hydrochloride USP, equivalent to 50 mg of pentazocine, and naloxone hydrochloride USP, equivalent to 0.5 mg of naloxone. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, dibasic calcium phosphate, D&amp;C Yellow No. 10 Al-lake, FD&amp;C Blue No. 1 Al-lake, FD&amp;C Yellow No. 6 Al-lake, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium lauryl sulfate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Pentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> to 60 mg (1 grain) of codeine. Onset of significant <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief are related both to dose and the severity of pretreatment <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Pentazocine weakly antagonizes the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.</p>
<p>Pentazocine is well absorbed from the gastrointestinal tract. Concentrations in plasma coincide closely with the onset, duration, and intensity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>; peak values occur 1 to 3 hours after oral administration. The half-life in plasma is 2 to 3 hours.</p>
<p>Pentazocine is metabolized in the liver and excreted primarily in the urine. Pentazocine passes into the fetal circulation.</p>
<p>Naloxone when administered orally at 0.5 mg has no pharmacologic activity. Naloxone hydrochloride administered parenterally at the same dose is an effective antagonist to pentazocine and a pure antagonist to narcotic analgesics.</p>
<p>Pentazocine and naloxone hydrochlorides tablets are a potent analgesic when administered orally. However the presence of naloxone in pentazocine and naloxone naloxone hydrochlorides tablets will prevent the effect of pentazocine if the product is misused by injection.</p>
<p>Studies in animals indicate that the presence of naloxone does not affect pentazocine <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> when the combination is given orally. If the combination is given by injection the action of pentazocine is neutralized.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<table frame="hsides">
<thead><tr class="First Last"><td class="Lrule" align="left" colspan="2" valign="top"></td></tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="left" valign="top">Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See <a href="#A37F1893-B7D1-4331-B73C-EA1493CE10A2">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a> section.)</td>
<td class="Rrule" align="left" valign="top"></td>
</tr></tbody>
</table>
<p class="First">Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Pentazocine and naloxone hydrochlorides tablets should not be administered to patients who are hypersensitive to either pentazocine or naloxone.</p>
<table frame="hsides">
<thead><tr class="First Last"><td class="Lrule" align="left" colspan="2" valign="top"></td></tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="left" valign="top">Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See <a href="#A37F1893-B7D1-4331-B73C-EA1493CE10A2">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a> section.)</td>
<td class="Rrule" align="left" valign="top"></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="A6F3CA5E-6C06-4ABE-8AFB-0C505A63D322"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>.</span> Pentazocine can cause a physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. (See <a href="#A37F1893-B7D1-4331-B73C-EA1493CE10A2">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>.)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>.</span> As in the case of other potent analgesics, the potential of pentazocine for elevating cerebrospinal fluid pressure may be attributed to CO<span class="Sub">2</span> retention due to the respiratory depressant effects of the drug. These effects may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, pentazocine can produce effects which may obscure the clinical course of patients with head injuries. In such patients, pentazocine must be used with extreme caution and only if its use is deemed essential.</p>
<p><span class="Italics">Usage with Alcohol.</span> Due to the potential for increased CNS depressant effects, alcohol should be used with caution in patients who are currently receiving pentazocine.</p>
<p><span class="Italics">Patients Receiving Narcotics.</span> Pentazocine is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the daily treatment of narcotic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, have experienced withdrawal symptoms after receiving pentazocine.</p>
<p><span class="Italics">Certain Respiratory Conditions.</span> Although <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> has rarely been reported after oral administration of pentazocine, the drug should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> from any cause, severely limited respiratory reserve, severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and other obstructive respiratory conditions, or <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>.</p>
<p><span class="Italics">Acute CNS Manifestations.</span> Patients receiving therapeutic doses of pentazocine have experienced <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (usually visual), <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be very closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>CNS Effect</h2>
<p class="First">Caution should be used when pentazocine is administered to patients prone to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have occurred in a few such patients in association with the use of pentazocine though no cause and effect relationship has been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Impaired Renal or Hepatic Function</h2>
<p class="First">Decreased metabolism of pentazocine by the liver in extensive liver disease may predispose to accentuation of side effects. Although laboratory tests have not indicated that pentazocine causes or increases renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the drug should be administered with caution to patients with such impairment.</p>
<p>In prescribing pentazocine for long-term use, the physician should take precautions to avoid increases in doses by the patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Biliary Surgery</h2>
<p class="First">Narcotic drug products are generally considered to elevate biliary tract pressure for varying periods following their administration. Some evidence suggests that pentazocine may differ from other marketed narcotics in this respect (i.e., it causes little or no elevation in biliary tract pressures). The clinical significance of these findings, however, is not yet known.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Since sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and occasional <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> have been noted, ambulatory patients should be warned not to operate machinery, drive cars, or unnecessarily expose themselves to hazards. Pentazocine may cause physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> when taken alone and may have additive CNS depressant properties when taken in combination with alcohol or other CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">As with all drugs, pentazocine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> who have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Italics">Usage with Alcohol:</span> See <a href="#A6F3CA5E-6C06-4ABE-8AFB-0C505A63D322">WARNINGS</a>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals to test for carcinogenesis have been performed with the components of pentazocine and naloxone hydrochlorides tablets.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.8"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with pentazocine and naloxone hydrochlorides. It is also not known whether pentazocine and naloxone hydrochlorides tablets can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Pentazocine and naloxone hydrochlorides tablets should be given to pregnant women only if clearly needed. However, animal reproduction studies with pentazocine have not demonstrated teratogenic or embryotoxic effects.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.9"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Patients receiving pentazocine during labor have experienced no adverse effects other than those that occur with commonly used analgesics. Pentazocine and naloxone hydrochlorides tablets should be used with caution in women delivering premature infants. The effect of pentazocine and naloxone hydrochlorides tablets on the mother and fetus, the duration of labor and delivery, the possibility that forceps delivery or other intervention or resuscitation of the newborn may be necessary, or the effect of pentazocine and naloxone hydrochlorides tablets on the later growth, development, and functional maturation of the child are unknown at the present time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.10"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when pentazocine and naloxone hydrochlorides tablets are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.11"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.12"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Controlled clinical studies of pentazocine and naloxone hydrochlorides tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses or effectiveness in analgesic activity between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Italics">Respiratory:</span> Rarely, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p><span class="Italics">Acute CNS Manifestations:</span> Patients receiving therapeutic doses of pentazocine have experienced <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (usually visual), <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be closely observed and vital signs checked. If the drug is reinstituted it should be done with caution since these acute CNS manifestations may recur.</p>
<p><span class="Italics">Other CNS Effects:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, sedation, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>; infrequently <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, disturbed dreams, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, visual blurring and focusing difficulty, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; and rarely <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Italics">Autonomic:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span>; infrequently <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; and rarely <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, rarely <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>.</p>
<p><span class="Italics">Allergic:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> of the face; <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, including <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed skin</span>, including plethora; infrequently <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and rarely <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Ophthalmic:</span> Visual blurring and focusing difficulty.</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> of white blood cells (especially granulocytes), which is usually reversible, moderate transient <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="A37F1893-B7D1-4331-B73C-EA1493CE10A2"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"><span class="Italics">Controlled Substance.</span> Pentazocine and naloxone hydrochlorides tablets are a Schedule IV controlled substance.</p>
<p>There have been some reports of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and of withdrawal symptoms with orally administered pentazocine. Patients with a history of <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> should be under close supervision while receiving pentazocine orally. There have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.</p>
<p>There have been instances of psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on parenteral pentazocine in patients with a history of drug abuse and rarely, in patients without such a history. Abrupt discontinuance following the extended use of parenteral pentazocine has resulted in withdrawal symptoms.</p>
<p>In prescribing pentazocine for chronic use, the physician should take precautions to avoid increases in dose by the patient.</p>
<p>The amount of naloxone present in pentazocine and naloxone hydrochlorides tablets (0.5 mg per tablet) has no action when taken orally and will not interfere with the pharmacologic action of pentazocine. However, this amount of naloxone given by injection has profound antagonistic action to narcotic analgesics.</p>
<p>Severe, even lethal, consequences may result from misuse of tablets by injection either alone or in combination with other substances, such as pulmonary emboli, <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>, ulceration and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, and withdrawal symptoms in narcotic dependent individuals.</p>
<p>Pentazocine and naloxone hydrochlorides tablets contain an opioid antagonist, naloxone (0.5 mg). Naloxone is inactive when administered orally at this dose, and its inclusion in pentazocine and naloxone hydrochlorides tablets is intended to curb a form of misuse of oral pentazocine. Parenterally, naloxone is an active narcotic antagonist. Thus, pentazocine and naloxone hydrochlorides tablets have a lower potential for parenteral misuse than the previous oral pentazocine hydrochloride formulation. However, it is still subject to patient misuse and abuse by the oral route.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Italics">Manifestations.</span> Clinical experience of overdosage with this oral medication has been insufficient to define the signs of this condition.</p>
<p><span class="Italics">Treatment. </span>Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> due to overdosage or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist.</p>
<table frame="hsides">
<thead><tr class="First Last"><td class="Lrule" align="left" colspan="2" valign="top"></td></tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="left" valign="top">Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See <a href="#A37F1893-B7D1-4331-B73C-EA1493CE10A2">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a> section.)</td>
<td class="Rrule" align="left" valign="top"></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Italics">Adults. </span>The usual initial adult dose is 1 tablet every three or four hours. This may be increased to 2 tablets when needed. Total daily dosage should not exceed 12 tablets.</p>
<p>When anti-inflammatory or antipyretic effects are desired in addition to <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, aspirin can be administered concomitantly with this product.</p>
<p><span class="Italics">Pediatric Patients.</span> Since clinical experience in pediatric patients under 12 years of age is limited, administration of this product in this age group is not recommended.</p>
<p><span class="Italics">Duration of Therapy.</span> Patients with <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> who receive pentazocine and naloxone hydrochlorides tablets orally for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> have only rarely been reported to experience withdrawal symptoms when administration was abruptly discontinued (see <a href="#A6F3CA5E-6C06-4ABE-8AFB-0C505A63D322">WARNINGS</a>). Tolerance to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of pentazocine has also been reported only rarely. However, there is no long-term experience with the oral administration of pentazocine and naloxone hydrochlorides tablets.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Pentazocine and Naloxone Hydrochlorides Tablets USP are light green, scored, capsule shaped tablets debossed <span class="Bold">395</span> to the left of the score, <span class="Bold">50</span> over <span class="Bold">0.5</span> to the right of the score and <span class="Bold">WATSON</span> on the reverse side.</p>
<p>They are supplied by <span class="Bold"> Keltman Pharmaceuticals Inc.</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">68387-531-30</td>
<td align="center">50 mg / 0.5 mg</td>
<td align="center">30 Tablets in a Plastic Bottle</td>
<td align="center">light green</td>
<td align="center">0591-0395</td>
</tr>
<tr>
<td align="center">68387-531-60</td>
<td align="center">50 mg / 0.5 mg</td>
<td align="center">60 Tablets in a Plastic Bottle</td>
<td align="center">light green</td>
<td align="center">0591-0395</td>
</tr>
<tr class="Last">
<td align="center">68387-531-12</td>
<td align="center">50 mg / 0.5 mg</td>
<td align="center">120 Tablets in a Plastic Bottle</td>
<td align="center">light green</td>
<td align="center">0591-0395</td>
</tr>
</tbody>
</table>
<p>Store at controlled room temperature 15°-30°C (59°-86°F). [See USP.]</p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
<p><span class="Bold">Watson Laboratories, Inc.</span><br>Corona, CA 92880 USA</p>
<p>This Product was Repackaged By Sandhills Packaging For:</p>
<p><span class="Bold">Keltman Pharmaceuticals Inc.</span><br>
1 Lakeland Square, Suite A<br>
Flowood, MS 39232<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>Label Image</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05a17f16-c982-4a54-80cd-079959ab49a7&amp;name=talwin%20nx%20lab.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PENTAZOCINE AND NALOXONE 		
					</strong><br><span class="contentTableReg">pentazocine hydrochloride and naloxone hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68387-531(NDC:0591-0395)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENTAZOCINE HYDROCHLORIDE</strong> (PENTAZOCINE) </td>
<td class="formItem">PENTAZOCINE HYDROCHLORIDE</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>NALOXONE HYDROCHLORIDE</strong> (NALOXONE) </td>
<td class="formItem">NALOXONE HYDROCHLORIDE</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (light green) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">2mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">watson;395;50;05</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68387-531-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68387-531-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68387-531-12</td>
<td class="formItem">120  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074736</td>
<td class="formItem">07/21/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Keltman Pharmaceuticals Inc.
							(362861077)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sandhills Packaging</td>
<td class="formItem"></td>
<td class="formItem">825138717</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>49cd8e11-2282-4c5b-bb4f-95526a9e2d6b</div>
<div>Set id: 05a17f16-c982-4a54-80cd-079959ab49a7</div>
<div>Version: 1</div>
<div>Effective Time: 20100720</div>
</div>
</div> <div class="DistributorName">Keltman Pharmaceuticals Inc.</div></p>
</body></html>
